*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

**IMPORTANT NOTICE:**

1.

2.

3.

□

2 ,
2022 2022

# I. KEY FINANCIAL INFORMATION

## (1) Major Accounting Information and Financial Indicators

□ √ Applicable □ Not applicable

| | The third quarter of 2022 | Increase/ decrease for the third quarter of 2022 over same period of last year | From the beginning of the year to the end of the Reporting Period | Increase/ decrease from the beginning of the year to the end of the Reporting Period over same period of last year |
|---|---|---|---|---|
| [illegible] | 1,636,515,303.73 | 7. 3% | 5,3 5,177,444.06 | 16.4 % |
| [illegible] | 141,11 ,351.11 | 14.41% | 652,257, 52.66 | 41.33% |
| [illegible] | 122, , ,12 .35 | -0.23% | 627,2 6,620.2 | 53.72% |
| [illegible] | | | . 71 ,2 1,0 . . 4 | . 6 6.10% |
| [illegible] | 0.0 62 | 14.3 % | 0.4445 | 41.34% |
| [illegible] | 0.0 62 | 14.3 % | 0.4445 | 41.34% |
| [illegible] | 1.14% | 0.0 % | 5.4 % | 1.53% |
| | As at the end of the Reporting Period | As at the end of last year | Increase/decrease for the end of the Reporting Period over the end of last year | |
| [illegible] | 21,46 ,0 ,221.2 | 1 ,10 ,175,266.7 | 12.36% | |
| [illegible] | 12,361,047,4 5. 3 | 11,411,354,455. | .32% | |

## (2) Items and Amounts of Extraordinary Profits and Losses

— □

*Currency: RMB Unit: Yuan*

| Items | Amounts from the third quarter of 2022 | Amounts from the beginning of the year to the end of the Reporting Period | Description |
|---|---|---|---|
| ( ) | 720, 70.62 | 65 ,736. 5 | |
| ( ) | 1 ,326,556. 5 | 32,71 , 75.34 | |
| 5 ( ) / 1 0. | | | |
| | | | |
| | | | |
| | | | |
| | | | |

## 1. Balance sheet items

| Items | As at the end of the Reporting Period | As at the end of last year | Year-on-year increase/ decrease | Reasons for changes |
|---|---|---|---|---|
| [illegible] | 6,070,007.3 | 10,00 ,75 . 6 | . 3 .36% | [illegible] |
| [illegible] | 6,503,40 , .32 | 4,707,54 ,5 2.43 | 3 .15% | [illegible] |
| [illegible] | 20,557,35 .51 | 14, . 2, 21.5 | 37.11% | [illegible] |
| [illegible] | 301,261,305.2 | 204,063, 3 .27 | 47.63% | [illegible] |
| [illegible] | 3,046, 2 , 03.75 | 1, 6,2 4,700.56 | 61.53% | [illegible] |
| [illegible] | 4 6,111, 43.1 | | | |
| | | | | |

| q7t-s | The Reporting Period | Same period of last year | Year-on-year increase/ decrease | Reasons for changes |
|---|---|---|---|---|
| | 1, 21,2 2.6 | 26,7 5, 4.6 | 405. 4% | |
| | 14,746,57 .3 | 6, 4,547.46 | 114.20% | |
| | 17,111, 17.61 | 11,7 5,24 . 0 | 45.07% | |
| | 4,475,25 .23 | 2, 23,54 .16 | 53.0 % | |
| | 777,1 4.3 | 1, 2 ,3 . 5 | 5 .70% | |
| | 41, 14,322.53 | 560,025,657.66 | 50.33% | |
| | | | | |

| Items | The Reporting Period | Same period of last year | Year-on-year increase/ decrease | Reasons for changes |
|---|---|---|---|---|
| | 1,053,241.5 | 6,437,623.23 | . 3.64% | |
| | 41,0 5,361.37 | 553,666,240. 2 | 51. 1% | |
| | 1 1,031,762.00 | . 6,603,6 3.55 | . 7.75% | |
| | 650,063,5 . .37 | 457,062,547.37 | 42.23% | |

## 3. Cash flow items

| Items | The Reporting Period | Same period of last year | Year-on-year increase/ decrease | Reasons for changes |
|---|---|---|---|---|
| | . 71 ,2 1,0 . . 4 | 122,722,54 . 0 | . 6 6.10% | |

| Items | The Reporting Period | Same period of last year | Year-on-year increase/ decrease | Reasons for changes |
|---|---|---|---|---|
| | 2,353,7 0.24 | 1,037,327, 22.77 | .77% | |
| | 70,216,60 .77 | 467,723, 55.63 | 307.43% | |
| | 10,5 5,0 0.37 | 27,3 5,4 4.60 | 13 .64% | |
| | 263, 74,37 .54 | 664, 31,021.34 | 60.32% | |

(, **API**–)

(, **CDMO**–)

**Heparin Industrial Chain Business**

4,611.3 ( 4,054.5 ).
50.2% (
43.5%) 4 . % (
56.5%)
2022,

2,315.2
31.1% 1,765.6
32.7%

26.2%
144.6%
77.5%

2,20 .6 ( 2,176.0 ),
1.5%

**CDMO Business**

74 ( 545.0 ).

( **Cytovance**–)

( & ),

1 .5% 21.3%





## II. INFORMATION OF THE SHAREHOLDERS

### (1) Table of total number of ordinary shareholders, the number of preferred shareholders whose voting rights have been restored and shareholdings of the top 10 shareholders

*Unit: Share(s)*

| Total number of ordinary shareholders as at the end of the Reporting Period | | 26,203 | Total number of preferred shareholders (if any) whose voting rights have been restored as at the end of the Reporting Period | | | 0 |
|---|---|---|---|---|---|---|
| Shareholding of the top 10 shareholders | | | | | | |
| Name of shareholder | Nature of shareholder | Shareholding percentage | Number of shares held | Number of shares held subject to selling restrictions | Status of shares pledged, marked or frozen | |
| | | | | | Status of shares | Number |
| # | | 32.31% | 474,02 ,.. | 0 | | |
| ( ) | | 27. 1% | 40 ,041,2 0 | 0 | | |
| | | 14. % | 21 , 4 ,4 0 | 0 | | |
| ( ) | | 3.16% | 46,425,600 | 0 | | |
| | | 2.75% | 40,320,000 | 0 | | |
| | | 1.64% | 24,130,651 | 0 | | |
| II | | 1.03% | 15,11 ,035 | 0 | | |
| | | 0.71% | 10,46 ,72 | 0 | | |
| | | 0.27% | 3,.. 7,265 | 0 | | |
| III | | 0.26% | 3, 6,264 | 0 | | |

| Shareholding of the top 10 shareholders who are not subject to selling restrictions | | | |
|---|---|---|---|
| Name of shareholder | Number of shares held not subject to selling restrictions | Type of shares | |
| | | Type of shares | Number |
| # | 474,02 ,... | | 474,02 ,... |
| ( ) | 40 ,041,2 0 | | 40 ,041,2 0 |
| (Note 1) | 21 , 4 ,4 0 | | 21 , 4 ,4 0 |
| ( ) | 46,425,600 | | 46,425,600 |
| | 40,320,000 | | 40,320,000 |
| | 24,130,651 | | 24,130,651 |
| | 15,11 ,035 | | 15,11 ,035 |
| | 10,46 ,72 | | 10,46 ,72 |
| | 3,. 7,265 | | 3,. 7,265 |
| | 3, 6,264 | | 3, 6,264 |
| Explanations of the related relationships or acting in concert among above shareholders | ( ) ( ) ( ) 3 . % 10 (香港中央結算(代理人)有限公司)' | | |
| Description of the top 10 shareholders' participation in financing and securities lending business (if any) | 10 60,000,000 4.0 % | | |

**(2) Statement of the total number of preferred shareholders of the Company and shareholdings of the top 10 preferred shareholders**

□ —

## III. OTHER IMPORTANT EVENTS

□ [illegible]

## IV. QUARTERLY FINANCIAL STATEMENTS

### (1) Financial Statements

### 1. Consolidated Balance Sheet

[illegible]

*Currency: RMB Unit: Yuan*

| Items | September 30, 2022 | [illegible] 1, 2022 |
|---|---|---|
| **Current assets:** | | |
| [illegible] | **2,947,231,848.07** | 2, 44,257,0 6.12 |
| [illegible] | | |
| [illegible] | | |
| [illegible] | **1,250,782,145.17** | 1,157,143.06 |
| [illegible] | | |
| [illegible] | **6,070,007.38** | 10,00 ,75 . 6 |
| [illegible] | **1,586,989,756.41** | 1,51 ,444,4 2.00 |
| [illegible] | | |
| [illegible] | **201,578,118.74** | 1 ,230,6 .3 |
| [illegible] | | |
| [illegible] | | |
| [illegible] | | |
| [illegible] | **173,625,047.99** | 243, 11,414.25 |
| [illegible] | | |
| [illegible] | | |
| [illegible] | | |
| [illegible] | **6,503,409,988.32** | 4,707,54 ,5 2.43 |
| [illegible] | **20,557,358.51** | 14, 2, 21.5 |
| [illegible] | | |
| [illegible] | | |
| [illegible] | **193,439,468.14** | 151,201,475.27 |
| [illegible] | **12,883,683,738.73** | 10,76 ,653,462 6 |

| Items | September 30, 2022 | 1, 2022 |
|---|---|---|
| | **433,516,795.52** | 3 5,7 6,645.07 |
| | | |
| | **461,708,853.20** | 3 3,7 2,1 5.25 |
| | | |
| | | |
| | | |
| | | |
| | **150,212,971.31** | 156,261,10 .6 |
| | **119,633,284.22** | 15 ,71 ,60 .60 |
| | **357,096,121.20** | 403,221,557.47 |
| | | |
| | **31,808,587.27** | |
| | | |
| | | |
| | | |
| | **1,669,376,634.61** | 1,413,635,355. 3 |
| | **3,364,908.32** | 3,76 ,4 0.51 |
| | **6,241,738,372.13** | 4,7 1,46 ,653.07 |
| **Non-current liabilities:** | | |
| | | |
| | **1,672,602,948.04** | 1,3 ,037,756. 6 |
| | **496,111,943.19** | 62,232,161.16 |
| | | |
| | | |
| | **104,240,297.81** | 104,000,6 7.4 |
| | **339,805.72** | 2 7, 66.0 |
| | **69,187,918.91** | 13 ,020,0 . .00 |
| | **9,766,766.17** | ,770,665.53 |
| | **19,742,990.60** | 16,672,645.6 |
| | **383,481,900.37** | 275,35 ,306.24 |
| | | |
| | **2,755,474,570.81** | 2,7 3,3 0,1 .14 |
| | **8,997,212,942.94** | 7,5 4, 5 , 51.21 |

| Items | September 30, 2022 | 1, 2022 |
|---|---|---|
| **Owners' equity:** | | |
| | **1,467,296,204.00** | 1,467,2 6,204.00 |
| | | |
| | | |
| | | |
| | **5,916,624,759.22** | 5, 43,653,365.2 |
| | | |
| | **192,462,995.09** | 1 3,356,155.51 |
| | | |
| | **536,799,924.51** | 536,7 , 24.51 |
| | | |
| | **4,247,863,603.11** | 3,646, 61,117.5 |
| | **12,361,047,485.93** | 11,411,354,455. |
| | **110,838,792.42** | 111, 60, 5 .6 |
| | **12,471,886,278.35** | 11,523,315,415.57 |
| | **21,469,099,221.29** | 1 ,10 ,175,266.7 |

| Items | Amount for current period | [illegible] |
|---|---|---|
| [illegible] | | |
| [illegible] | | |
| [illegible] | **–14,746,578.38** | 6, 4,547.46 |
| [illegible] | **–17,111,917.61** | 11,7 5,24 . 0 |
| [illegible] | **–4,475,259.23** | 2, 23,54 .16 |
| [illegible] | **777,184.39** | 1, 2 ,3 . 5 |
| [illegible] | **841,914,322.53** | 560,025,657.66 |
| [illegible] | **234,280.43** | 7 ,206.4 |
| [illegible] | **1,053,241.59** | 6,437,623.23 |
| [illegible] | **841,095,361.37** | 553,666,240. 2 |
| [illegible] | **191,031,762.00** | 6,603,6 3.55 |
| [illegible] | **650,063,599.37** | 457,062,547.37 |
| [illegible] | | |
| 1.[illegible] | **650,063,599.37** | 457,062,547.37 |
| 2.[illegible] | | |
| [illegible] | | |
| 1.[illegible] | **652,257,852.66** | 461,505,654.17 |
| 2.[illegible] | **–2,194,253.29** | 4,443,106. 0 |
| [illegible] | **377,190,878.62** | 2, 70,4 7.52 |
| [illegible] | **375,819,150.60** | 3,0 0,457.04 |
| [illegible] | **49,442,159.49** | 1,00 ,65 . 5 |

| Items | Amount for current period | |
|---|---|---|
| 1. | **56,813,153.88** | 3,261,531.31 |
| 2. | | |
| 3. | **–7,370,994.39** | 4,270,1 1.26 |
| 4. | | |
| 5. | | |
| (II) | **326,376,991.11** | 4,0 ,116. |
| 1. | **14,161,222.65** | 10,602,42 .21 |
| 2. | | |
| 3. | | |
| 4. | | |
| 5. | | |
| 6. | **312,215,768.46** | 14,6 1,546.20 |
| 7. | | |
| | **1,371,728.02** | 10 , 6 .52 |
| II | **1,027,254,477.99** | 460,033,034. |
| (I) | **1,028,077,003.26** | 464,5 6,111.21 |

## 3. Consolidated Cash Flow Statement from the beginning of the year to the end of the Reporting Period

*Currency: RMB Unit: Yuan*

| Items | Amount for current period | |
|---|---|---|
| | | |
| | **5,636,346,156.36** | 4,701,1 0,656. 3 |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | **375,424,510.04** | 276, 73,471.02 |
| | **72,009,536.97** | 35, , ,051.21 |
| | **6,083,780,203.37** | 5,014,053,17 .06 |
| | **5,322,980,702.09** | 3,625,4 , ,06 , 1 |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| Items | Amount for current period | |
|---|---|---|
| | **717,088,081.77** | 5 5,42 ,54 . |
| | **211,193,118.23** | 1 5,176,0 3.71 |
| | **551,799,391.12** | 4 5,235, 27.66 |
| | **6,803,061,293.21** | 4, 1,330,630.26 |
| | **–719,281,089.84** | 122,722,54 . 0 |
| | | |
| | **2,470,118,418.02** | 2,427,26 ,37 .42 |
| | **93,980,404.15** | 5 7, 1,353.51 |
| | **151,844.45** | 170,362.74 |
| | | |
| | **2,020,354,688.99** | 1, 0 ,6 0,742. 0 |
| | **4,584,605,355.61** | 4, 25,011, 37.57 |
| | **162,563,223.26** | 144,755,500.41 |
| | **2,749,695,820.61** | 1,504,112,301.61 |
| | | |
| | | |
| | **1,669,992,531.50** | 2,23 , 16,112.7 |
| | **4,582,251,575.37** | 3, 7,6 3, 14. 0 |
| | **2,353,780.24** | 1,037,327, 22.77 |
| | | |
| | | |
| | | |
| | **4,928,822,097.65** | 2, 0,440,715.27 |
| | **10,997,692.25** | |
| | **4,939,819,789.90** | 2, 0,440,715.27 |
| | **3,627,473,860.07** | 2, 3 , 17, 57.11 |
| | **209,613,269.79** | 3 2,0 ,306.73 |

| Items | Amount for current period | |
|---|---|---|
| | | |
| | **132,516,051.27** | 36,15 ,407.06 |
| | **3,969,603,181.13** | 3,35 ,164,670. 0 |
| | **970,216,608.77** | . 467,723, 55.63 |
| | **10,585,080.37** | . 27,3 5,4 4.60 |
| | **263,874,379.54** | 664, 31,021.34 |
| | **1,479,633,434.04** | 1,330,245,256.17 |
| | **1,743,507,813.58** | 1, . 5,176,277.51 |

## (2) Audit Report